ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025
[Fufang Changtai Decoction Inhibites Colorectal Cancer Through Ferroptosis: Investigation of the Underlying Mechanism].
Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the underlying mechanisms of the effect of Fufang Changtai Decoction (FFCT) in inhibiting colorectal cancer (CRC) through the ferroptosis pathway using network pharmacology combined with experimental validation. Methods: The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and Swiss Target Prediction databases were employed for the systematic screening of potent active ingredients and therapeutic targets of FFCT. In addition, the identification of CRC-associated genes and ferroptosis-related genes (FRGs) was accomplished using the Gene Cards and FerrDb databases, respectively. Venn diagrams, coupled with Cytoscape software, facilitated the comprehensive analysis of key FRGs involved in FFCT's intervention in CRC by mapping the TCM compound-therapeutic target network. Transmission electron microscopy was used to examine the mitochondrial ultrastructure of SW480 and HCT116, 2 Human CRC cell lines, after treatment with FFCT-containing serum. Intracellular reactive oxygen species (ROS) levels were measured using a ROS detection kit. To assess the role of ferroptosis, ferroptosis inhibitor liproxstatin-1 (Lip-1) was co-administered with FFCT-containing serum. The effects on cancer cell viability and proliferation were evaluated using CCK-8 and colony formation assays. Key molecular targets involved in the regulatory effects of FFCT on the expression of FRGs were further analyzed using PCR Array and Western blot. The findings were then validated with human CRC tissue microarrays. Results: A total of 103 active ingredients of FFCT, 739 therapeutic targets, 9101 disease-related genes, and 564 FRGs were identified. Venn diagram analysis identified 81 FRGs associated with FFCT intervention. Network analysis revealed that NQO1, TP53, and PTGS2 served as hub nodes in the regulatory network. Findings from the Conclusion: FFCT may induce intracellular ferroptosis by downregulating the oncogenic gene NQO1, thereby exerting anti-CRC effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.